Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Aims of the trial: Establishing the profile of the growth factors and other mediators of
angiogenesis in different ocular fluids (aqueous humour, vitreous gel and ocular liquid in
vitrectomized eyes), in the 2 most frequent proliferative retinopathies - diabetic
proliferative retinopathy (PDR) and exudative age related macular degeneration (AMD).
Following up the dynamic of this profile before and after intravitreal administration of
Bevacizumab (Avastin) as an anti-VEGF blocker.
Materials: The research will be conducted on the following categories of patients groups:
- nondiabetic patients without AMD or any other diagnosed proliferative ocular disease
(controls)
- patients with age related macular degeneration (AMD groups) before and after
intravitreal injections with Avastin
- diabetic patients with different types of diabetic retinopathy, before and after
intravitreal Avastin (diabetic groups) Methods: Samples from different ocular fluids
will be collected from each group of patients. 10 growth factors and other 10 cytokines
will be determined in the ocular fluids samples.
Results: The results from the biochemical measurements will be statistically interpreted in
order to obtain conclusions for the clinical practice.
Conclusions: The conclusions of this trial will be used exclusively for research publications
and communications, as well as for clinical practice.